Anti-virus therapy for respiratory diseases

Details Anti-virus therapy for respiratory diseases Anti-virus therapy for respiratory diseases

2006-09-08

2009-08-04

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

Reexamination Certificate

active

07569216

ABSTRACT:
The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-λ for the same purpose.

REFERENCES:
patent: 6030609 (2000-02-01), Panuska et al.
patent: 6596260 (2003-07-01), Brugger et al.
patent: 2001/0031263 (2001-10-01), Panuska et al.
patent: 2003/0072718 (2003-04-01), Platz et al.
patent: 2004/0037809 (2004-02-01), Quay et al.
patent: 1 133 997 (2001-09-01), None
patent: WO-02/36628 (2002-05-01), None
patent: WO-02/072019 (2002-09-01), None
patent: WO-03/066002 (2003-08-01), None
patent: WO-2004/037995 (2004-05-01), None
patent: WO-2005/023862 (2005-03-01), None
patent: WO-2005/087253 (2005-09-01), None
patent: WO-2005/097165 (2005-10-01), None
Edwards et al (Annual Review of Biomedical Engineering 4:93-107, 2002).
Edwards et al (Pulmonary Pharmacology & Therapeutics 19:320-332, 2006).
C.E. Johnson. “Principles of nebulizer-delivered drug therapy for asthma.” American Journal of Hospital Pharmacy, vol. 46, Issue 9, 1845-1855 (1989).
Contoli et al., Nature Medicine (2006) 12(9):1023-1026.
Bartlett et al., Journal of General Virology (2005) 86(6):1589-1596.
Coccia et al., European Journal of Immunology (2004) 34:796-805.
International Search Report for PCT/GB2006/050281, mailed on Mar. 19, 2007, 5 pages.
Kotenko et al., Nature Immunology (2003) 4:69-77.
Meager et al., Cytokine (2005) 31(2):109-118.
Osterlund et al., Journal of Virology (2005) 79(15):9608-9617.
Sheppard et al., Nature Immunology (2003) 4:63-68.
GB Search Report and Opinion for GB 0405634.7, dated Aug. 16, 2004.
Takahashi et al., “The Japanese Interferon Study Group (JISG) has established the efficacy of human interferon-β for serious CMV pneumonitis in kidney recipients,” Transplantation Int. (1992) 5(Suppl. 1):S133-S137.
Takahashi et al., “Effect of Human Interferon-β on Life-Threatening Viral Pneumonitis in Kidney Transplant Recipients,” Transplantation Proceedings (1987) XIX(5):4089-4095.
Satoh et al., “Induction of Tissue 2′5′ AS and Suppression of Delayed Type of Asthma Reaction by Oral Administration of IFN-β in Guinea Pig Asthma Model,” J. Interferon and Cytokine Res. (1997) 17:S96, W40.
Satoh et al., “Suppression of Late Asthmatic Response by Low-Dose Oral Administration of Interferon-β in the Guinea Pig Model of Asthma,” J. Interferon and Cytokine Res. (1999) 19:887-894.
Hensley et al., “Interferon-β 1a and SARS Coronavirus Replication,” Emerging Infectious Disease (2004) 10:317-319.
Cinatl et al., “Treatment of SARS with human interferons,” Lancet (2003) 362:293-294.
Bradley et al., “A Phase III Comparison of Radiation Therapy with or without Recombinant β-Interferon for Poor-Risk Patients with Locally Advanced Non-Small-Cell Lung Cancer (RTOG 93-04),” Int. J. Radiation Oncology Biol. Phys. (2002) 52:1173-1179.
Hill et al., “Effect of an Interferon Inducer on Human Respiratory Viruses,” Bacteriological Proceedings (1969) 69:149, V3.
Soike et al., “Effect of Interferon on Respiratory Infections of Animals,” Texas Reports on Biology and Medicine (1977) 35:455-460.
International Search Report for PCT/GB2005/050031, mailed on Sep. 30, 2005, 4 pages.
Overlack et al., “Clinical and Functional Course of COPD in Hypertensive Patients with Concomitant Chronic Bronchitis and Emphysema During Treatment with an Ace Inhibitor, Perindopril,” Journal of Drug Development (1993) 6:5-9.
Higgins et al., “Interferon-βserAs Prophylaxis Against Experimental Rhinovirus Infection in Volunteers,” Journal of Interferon Research (1986) 6:153-159.
Sperber et al., “Comparative Susceptibility of Respiratory Viruses to Recombinant Interferons-α2band -β,” Journal of Interferon Research (1989) 9:285-293.
Sperber et al., “Otologic Effects of Interferon Beta Serine in Experimental Rhinovirus Colds,” Arch. Otolaryngol. Head Neck Surg. (1992) 118:933-936.
Sperber et al., “Ineffectiveness of Recombinant Interferon-βserineNasal Drops for Prophylaxis of Natural Colds,” J. Infectious Dis. (1989) 160:700-705.
Wark et al., “Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus,” J. Exp. Med. (2005) 201:937-947.
Contoli et al., “Rhinovirus induces IFN-Lambdas in bronchial epithelial cells: new cytokines with anti-viral activity against rhinovirus,” European Respiratory Journal (2005) 26(Suppl. 49 Sept.) p. 122, PP50.

Affiliated with

Also associated with

Rating

Anti-virus therapy for respiratory diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-virus therapy for respiratory diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-virus therapy for respiratory diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4079290